Binney Street Capital
VC Fund
Boston, United States
Binney Street Capital is a venture fund associated with the Dana-Farber Cancer Institute in Boston. It aims to accelerate the development of new research and technologies to treat uncurable diseases by investing in Dana-Farber startup companies.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Binney Street Capital invests in
Stages Binney Street Capital invests in
Countries Binney Street Capital invests in
Investment Focus
Industry
- Biotechnology 5 (71%)
- Health Care 4 (57%)
- Biopharma 2 (29%)
- Life Science 2 (29%)
- Therapeutics 2 (29%)
Stage
- Series A 3 (43%)
- Series B 3 (43%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neomorph
|
Neomorph is building a leading protein degradation entity, focused on “molecular glue” degraders. Its mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against “undruggable targets.” | $100M / Series B / Apr 13, 2026 | |
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M / Series B / Jan 12, 2026 | |
Predicta Biosciences
|
Predicta Biosciences is a precision oncology firm that integrates multiomics and liquid biopsies to create diagnostic tools and therapies. They also have an in-house pipeline for novel immunotherapy targets in pre-clinical stages. | $23.4M / Series A / Oct 01, 2025 | |
NextPoint Therapeutics
|
NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. | $42.5M / Series B / Feb 14, 2024 | |
|
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $57M / Series A / Oct 05, 2023 | |
|
NextPoint Therapeutics
|
NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. | $80M / Series B / Jan 10, 2023 | |
Kojin Therapeutics
|
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases.The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital. | $60M / Series A / Jun 09, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Binney Street Capital invest in?
Binney Street Capital invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Binney Street Capital last invest?
The most recent investment recorded for Binney Street Capital closed in Apr 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
